Pharmacokinetics of netilmicin in the presence of normal or impaired renal function. 1978

G Humbert, and A Leroy, and J P Fillastre, and G Oksenhendler

A pharmacokinetic study of netilmicin was conducted in 12 healthy subjects and 24 subjects with chronic renal failure. After intramuscular administrations of 2 and 3 mg of netilmicin per kg in normal subjects, the mean peak serum concentrations were 5.46 and 8.83 mug/ml, respectively. After intravenous infusions of identical doses, the mean maximum serum levels, occurring at the end of the infusion, were 11.79 and 15.75 mug/ml, respectively. The pharmacokinetic data were very similar via the two routes of administration and for the two doses. The elimination half-life was 2.20 h, and 80 to 90% of the injected dose was recovered in urine during the first 24 h. After intramuscular administration of 2 mg/kg in subjects with chronic renal impairment, the elimination half-life increased to 29.48 h, and urinary elimination was inversely related to the degree of impairment. A study was conducted throughout hemodialysis sessions: serum concentrations decreased by 63.3%. The linear relationships between the elimination rate constant and creatinine clearance and the elimination half-life and serum creatinine allowed us to establish dosage schedules according to the degree of renal failure.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D005839 Gentamicins A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS. Gentamicin Sulfate (USP),Gentamycin,G-Myticin,Garamycin,Gentacycol,Gentamicin,Gentamicin Sulfate,Gentamycins,Gentavet,Genticin,G Myticin,GMyticin,Sulfate, Gentamicin
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

G Humbert, and A Leroy, and J P Fillastre, and G Oksenhendler
October 1987, Antimicrobial agents and chemotherapy,
G Humbert, and A Leroy, and J P Fillastre, and G Oksenhendler
September 1979, European journal of clinical pharmacology,
G Humbert, and A Leroy, and J P Fillastre, and G Oksenhendler
November 1994, Journal of clinical pharmacology,
G Humbert, and A Leroy, and J P Fillastre, and G Oksenhendler
January 1985, Drugs,
G Humbert, and A Leroy, and J P Fillastre, and G Oksenhendler
January 1997, European journal of clinical pharmacology,
G Humbert, and A Leroy, and J P Fillastre, and G Oksenhendler
April 1979, International journal of clinical pharmacology and biopharmacy,
G Humbert, and A Leroy, and J P Fillastre, and G Oksenhendler
July 1983, The Journal of antimicrobial chemotherapy,
G Humbert, and A Leroy, and J P Fillastre, and G Oksenhendler
January 1984, Arzneimittel-Forschung,
G Humbert, and A Leroy, and J P Fillastre, and G Oksenhendler
May 1988, Arzneimittel-Forschung,
G Humbert, and A Leroy, and J P Fillastre, and G Oksenhendler
January 1983, Arzneimittel-Forschung,
Copied contents to your clipboard!